Utility of Bronchoscopy in Patients With Haemoptysis and Negative Chest CT Scan (ULYSSES)
Recruiting
- Conditions
- Hemoptysis
- Registration Number
- NCT05634200
- Lead Sponsor
- University of Milan
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
Inclusion Criteria:<br><br> - =18 years old<br><br> - Haemoptysis of unknown origin<br><br> - Negative or non-diagnostic chest CT scan<br><br>Exclusion Criteria:<br><br> - Known bleeding lesions of the upper or lower respiratory airways<br><br> - Chest CT scan diagnostic for hemoptysis etiology<br><br> - Refusal to sign the informed consent<br><br> - Refusal of bronchoscopy
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To evaluate the proportion of patients with haemoptysis and negative/non-diagnostic CT scans in whom bronchoscopy allows an aetiological (i.e., endoscopic and/or microbiological and/or anatomopathological) diagnosis
- Secondary Outcome Measures
Name Time Method To evaluate the proportion of patients in whom bronchoscopy may detect occult endobronchial neoplasms (not detected with chest CT scan);To evaluate the proportion of patients in whom bronchoscopy may identify the source of the bleeding;To evaluate the proportion of patients with haemoptysis and negative chest CT scan in whom bronchoscopic findings may induce variation in the treatment of the patients;To evaluate the proportion of patients with a negative bronchoscopy at baseline, in whom a an endoscopic examination performed during the follow-up for recurrent haemoptysis may allow an aetiological diagnosis;To evaluate the proportion of patients with a negative chest CT scan and bronchoscopy in whom lung cancer may be diagnosed during the follow-up;To evaluate the main clinical characteristics (e.g., severity of haemoptysis) of these patients, the rate and severity of symptom recurrence and the mortality rate after one year of follow-up.